HCPCS code J9130: Dacarbazine injection, per 100 mg2026 Medicare rate & RVUs in Massachusetts
Reports dacarbazine, an antineoplastic drug used in regimens for melanoma, Hodgkin lymphoma, and soft-tissue sarcoma, in 100 mg units.
CMS doesn’t publish an office rate for J9130 in Massachusetts.
Medicare allowed amount for participating (non-QP) physicians, before deductible, coinsurance and claim adjustments. Not a patient’s bill or a hospital charge.
Your location
On this page 9 sections
What J9130 covers
Dacarbazine is an antineoplastic drug administered intravenously in chemotherapy treatment. Oncology practices and hospital outpatient departments report the drug when it is furnished for a patient’s treatment; clinical uses include melanoma, Hodgkin lymphoma, and soft-tissue sarcoma. The drug code identifies dacarbazine, not the infusion or other administration service.
CMS assigns J9130 physician fee schedule status E, meaning it is excluded from the physician fee schedule. When Medicare covers the drug, payment is under another method; CMS classifies it as a Part B drug generally priced from its quarterly Average Sales Price files. Special Medicare coverage instructions apply. Each billing unit represents 100 mg of dacarbazine, so the units reflect the administered amount in 100 mg increments. Report the chemotherapy administration separately when it is separately reportable.
This summary was written with AI assistance from CMS physician fee schedule data and checked against the CMS billing rules shown here. Rates on this page come directly from CMS files.
Where J9130 pays more and less in Massachusetts
| Payment locality | Office | Facility |
|---|---|---|
| Metropolitan Boston, MA | Unavailable | Unavailable |
| Rest of Massachusetts | Unavailable | Unavailable |
How the J9130 rate is calculated
Each of J9130’s three RVUs is multiplied by a geographic index (GPCI) for the payment locality, added up, and multiplied by the conversion factor. Drag the indexes or enter a ZIP to see what moves the rate.
How the rate is built · J9130
RVUs × geographic indexes × conversion factor
Work0.00
0.00 RVUs× 1.000 GPCI
Practice expense0.00
0.00 RVUs× 1.000 GPCI
Malpractice0.00
0.00 RVUs× 1.000 GPCI
Adjusted RVUs
0.0000
Conversion factor
$33.4009
Medicare rate
$0.00
Every GPCI starts at 1.000, the national rate. Enter a ZIP or drag a slider.
Payment rules and modifiers for J9130
J9130 has no global surgery period, no multiple-procedure, bilateral or assistant-at-surgery adjustment, and no professional/technical split. What changes the payment is where the service happens: the place of service on the claim decides whether Medicare pays the office or the facility rate.
Place of service · J9130
Which rate does Medicare pay?
The POS code on the claim line (CMS-1500 box 24B).
POS 11 · non-facility rate · national
—
J9130 isn’t priced in this setting.
J9130 compared with similar codes
Compare codes · National
4 codes, side by side
How to choose
- J9100Cytarabine injectionPer 100 mg
- J9100 identifies cytarabine, not dacarbazine. Choose according to the drug administered, even if both are used in cancer treatment.
- J9120DactinomycinPer 0.5 mg
- J9120 identifies dactinomycin. It is a different antineoplastic drug, not another code for dacarbazine.
- J9150Daunorubicin injectionPer 10 mg
- J9150 identifies daunorubicin. Use J9130 only when dacarbazine is the drug furnished.
J9130 billing questions
How many units should be reported?
Each unit represents 100 mg of dacarbazine. Calculate units from the administered dose in 100 mg increments.
Does J9130 include the infusion service?
No. J9130 identifies the dacarbazine drug; report the chemotherapy administration service separately when it is separately reportable.
How is J9130 paid under Medicare?
CMS status E excludes it from the physician fee schedule. When covered, it is a Part B drug generally priced using CMS quarterly ASP files, and special Medicare coverage instructions apply.
How do I distinguish J9130 from other chemotherapy drug codes?
Select the code for the drug actually furnished. J9130 is dacarbazine; codes for cytarabine, dactinomycin, or daunorubicin identify different drugs, even when used to treat cancers that overlap.
What documentation supports the units?
The record should identify dacarbazine and the amount administered so the billed units can be determined in 100 mg increments.
Where these rates come from
FeeBase calculates base physician payments from CMS work, practice-expense and malpractice RVUs, adjusted by each locality’s geographic indexes and the conversion factor. Services without a published rate are labeled, never given a made-up amount. Amounts are Medicare allowed amounts before claim adjustments: not a patient’s bill or a commercial rate.
CMS RVU26D · effective Oct 1, 2026 through the day before Jan 1, 2027
Fee sheets · Coming soon
Put J9130 and the rest of your codes on one sheet
Your codes at your locality, with payer contracts beside Medicare.
Join the waitlist